“A recently presented poster session from RAD 2023 evaluated a gene expression based molecular test’s differential diagnosis of psoriasis and eczema.

Dermagnostix is featured in the journal series ‘Karger Kompass’ aimed at clinicians and specialists in private practice with a focus on young, committed physicians with four specialist target groups of pneumologists, dermatologists, oncologists and ophthalmologists.

Dermagnostix announces mid-term analysis of ongoing 3-year clinical utility study on PsorX classifier sponsored by the DGUV (German Accident Insurance Company) was presented at ADF.

An exciting week for Dermagnostix at the MEDICA and DxPx!

Many people suffer from inflammatory skin diseases such as psoriasis or eczema like atopic dermatitis – but it’s often not clear exactly what the cause is: conventional methods are not always conclusive.

Dermagnostix GmbH has developed a rapid test to differentiate between psoriasis and eczema. This test is currently undergoing preclinical testing, with market launch planned for 2023.